Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial

AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of... http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Lancet Infectious Diseases Unpaywall

AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial

AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial

The Lancet Infectious DiseasesDec 1, 2017

Loading next page...
 
/lp/unpaywall/aq-13-an-investigational-antimalarial-versus-artemether-plus-40KI2zbbLX

References (29)

Publisher
Unpaywall
ISSN
1473-3099
DOI
10.1016/s1473-3099(17)30365-1
Publisher site
See Article on Publisher Site

Abstract

Journal

The Lancet Infectious DiseasesUnpaywall

Published: Dec 1, 2017

There are no references for this article.